Celularity Inc. (CELU)
| Market Cap | 43.16M -20.7% |
| Revenue (ttm) | 18.97M -62.8% |
| Net Income | -71.31M |
| EPS | -2.65 |
| Shares Out | 32.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,597 |
| Open | 1.280 |
| Previous Close | 1.310 |
| Day's Range | 1.270 - 1.350 |
| 52-Week Range | 0.560 - 2.550 |
| Beta | 0.78 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About CELU
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn’s) and degenerative disease; and PDA-002 for treating multip... [Read more]
Financial Performance
In 2025, Celularity's revenue was $26.55 million, a decrease of -51.03% compared to the previous year's $54.22 million. Losses were -$91.80 million, 58.6% more than in 2024.
Financial StatementsNews
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
Celularity highlights Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative medicine
Celularity announces Jain to join Board of Directors
Celularity (CELU) announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences, will join its Board of Directors.
Celularity Announces Naveen Jain to Join Board of Directors
FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company, today announced that Naveen Jain, founder and Ch...
Celularity Quarterly report: Q1 2026
Celularity has published its Q1 2026 quarterly earnings report on September 29, 2026.
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
Celularity closes $10 million financing in an up to $28 million recapitalization, advancing growth and targeting positive operating cash flow by Q1 2027.
Why Is Penny Stock Celularity (CELU) Up 115% Today?
Celularity stock rallied 115.81% on Thursday alongside a new agreement with MuseCell Innovations.
Celularity, MuseCell Innovations announce U.S. manufacturing collaboration
Celularity (CELU) and MuseCell Innovations announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCe...
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
FLORHAM PARK, N.J. & SINGAPORE--(BUSINESS WIRE)--Celularity Inc. and MuseCell Innovations announce U.S. manufacturing partnership for production of Dezawa MuseCells in Florham Park, NJ facility.
Celularity provides updates regarding NASDAQ listing compliance
Celularity (CELU) announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has…
Celularity Provides Update Regarding Nasdaq Listing Compliance
FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualif...
Penny Stocks: Why Is Celularity (CELU) Stock Trending Today?
Celularity Inc. ($CELU), a micro-cap biotech company developing placental-derived cell therapies, is drawing investor attention after a cluster of company-specific updates gave traders a fresh turnaro...
Celularity announces cenplacel-L availability for investigational use in Florida
Celularity (CELU) and Fountain Life announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State ...
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
FLORHAM PARK, N.J. and ORLANDO, Fla.
Celularity Releases CEO Letter to Shareholders
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placenta...
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placenta...
Celularity Receives Nasdaq Notice Regarding Form 10-Q
FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received a ...
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
Company advances focused strategy, strengthens balance sheet and positions business for long-term growth Company advances focused strategy, strengthens balance sheet and positions business for long-te...
Celularity Annual report: Q4 2025
Celularity has published its Q4 2025 annual report on April 30, 2026.
NEXGEL Appoints Ian Blackman as Chief Financial Officer
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or...
NexGel closes acquisition of products from Celularity
NexGel (NXGL) announced the closing of its previously announced license and acquisition of a portfolio of commercial-stage regenerative biomaterials products from Celularity (CELU), a regenerative and...
Celularity announces closing of transaction with NexGel
Celularity (CELU) announced the closing of its previously announced transaction with NexGel, pursuant to which NexGel acquired certain commercial and other assets related to Celularity’s biomaterials ...
Celularity Announces Closing of Transaction with NexGel
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its...
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April 16,...
NexGel announces terms of agreement of license for products from Celularity
NexGel (NXGL) announced the consideration terms of its previously announced agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (CELU), a...
Celularity reiterates strategic commercialization partnership with NEXGEL
Celularity (CELU) reiterated that its strategic commercialization partnership with NEXGEL (NXGL) is a focused effort by the two companies to rapidly capitalize on renewed regulatory and reimbursement ...